Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mineralys Therapeutics, Inc. - Common Stock (NQ:MLYS)

25.93 -0.41 (-1.56%)
Streaming Delayed Price Updated: 3:00 PM EDT, Aug 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 474,791
Open 26.30
Bid (Size) 25.91 (400)
Ask (Size) 25.94 (100)
Prev. Close 26.34
Today's Range 25.57 - 26.30
52wk Range 14.53 - 47.65
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Mineralys (MLYS) Q2 2026 Earnings Call Transcript ↗
Lorundrostat advances toward December FDA decision as company ramps commercial launch. 
Via The Motley Fool
Topics Earnings
News headline image
Mineralys Therapeutics Q2 Earnings Call Highlights ↗
Mineralys Therapeutics (NASDAQ:MLYS) said it is continuing commercial-launch preparations for lorundrostat ahead of its December 22 Prescription Drug User Fee Act target date, while reporting a wider... 
Via MarketBeat
Topics Earnings Initial Public Offering

Performance

YTD
-27.4%
-27.4%
1 Month
-4.7%
-4.7%
3 Month
-13.5%
-13.5%
6 Month
-13.5%
-13.5%
1 Year
+75.9%
+75.9%

More News

Read More
News headline image
A Mineralys Insider Banked a $557,000 Options Gain Before a December FDA Date ↗
Via The Motley Fool
Topics Regulatory Compliance
Mineralys Therapeutics Inc (NASDAQ:MLYS) First Quarter 2026 Results Show Modest Market Reaction to FDA NDA Acceptance ↗
Via Chartmill
Mineralys Therapeutics Inc (NASDAQ:MLYS) Reports Q4 2025 EPS Beat and Key FDA NDA Acceptance for Lorundrostat ↗
Via Chartmill
News headline image
Earnings Scheduled For November 10, 2025 ↗
Via Benzinga
News headline image
What to Know About This Mineralys Insider Sale Before a December FDA Date ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What a $350,000 Insider Sale Might Mean for Mineralys Ahead of December FDA Decision ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Mineralys (MLYS) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Mineralys Therapeutics' CEO Sold Shares Worth $1.97 Million. Should Investors Avoid the Stock? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Mineralys (MLYS) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Leaned Into 2025's Big Biotech Rally with a $9.5 Million Bet on Mineralys ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
MINERALYS THERAPEUTICS INC (NASDAQ:MLYS) Beats Q3 2025 EPS Estimates and Advances Key Drug Candidate ↗
Via Chartmill
News headline image
Uncovering Potential: Mineralys Therapeutics's Earnings Preview ↗
Via Benzinga
News headline image
These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing? ↗
Via The Motley Fool
News headline image
It's a Small World: 3 Stocks Leading the Sudden Rebound in Small Caps ↗
Via The Motley Fool
Topics Economy Stocks
News headline image
These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts ↗
Via The Motley Fool
News headline image
Bruker, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
Via Benzinga
News headline image
Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
Here are the top movers in Tuesday's session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Via Benzinga

Frequently Asked Questions

Is Mineralys Therapeutics, Inc. - Common Stock publicly traded?
Yes, Mineralys Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Mineralys Therapeutics, Inc. - Common Stock trade on?
Mineralys Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Mineralys Therapeutics, Inc. - Common Stock?
The ticker symbol for Mineralys Therapeutics, Inc. - Common Stock is MLYS on the Nasdaq Stock Market
What is the current price of Mineralys Therapeutics, Inc. - Common Stock?
The current price of Mineralys Therapeutics, Inc. - Common Stock is 25.93
When was Mineralys Therapeutics, Inc. - Common Stock last traded?
The last trade of Mineralys Therapeutics, Inc. - Common Stock was at 08/26/26 03:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.